Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;4(Suppl 1):S14-6.
doi: 10.4103/0975-7406.94121.

Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene

B Divyakant Patel  1 , R Valay Modi, N Alok Thakkar, A Arpita Patel, P Hetal Thakkar
Affiliations

Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene

B Divyakant Patel et al. J Pharm Bioallied Sci. 2012 Mar.

Abstract

The objective of this study was to increase the oral bioavailability of Raloxifene having an absolute bioavailability only 2% due to extensive first pass hepatic metabolism by incorporating it in Solid Lipid Nanoparticles (SLNs). The optimized RSLNs prepared by Ultrasonic Emulsification and Low Temperature Solidification method showed the mean particle size, zeta potential and percentage drug entrapment of 101.4±3.5 nm, 19.4±0.279 mv, 97.67±1.02% respectively. The in-vitro intestinal permeability study indicated significantly higher permeation of the RSLNs than the marketed preparation. The in-vivo studies showed that pharmacokinetic parameters for the RSLNs were 3.5 times higher than the marketed preparation indicating significant increase in the oral bioavailability of the Raloxifene.

Keywords: Drug entrapment; estrogen; solvent emulsification; zeta potential.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
DSC thermogram of RSLNs
Figure 2
Figure 2
SEM Image of RSLNs
See this image and copyright information in PMC

References

    1. Zurmuhlen C, Mehnert SW. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998;45(2):149–155. - PubMed
    1. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001;47(2-3):165–196. - PubMed
    1. Mehnert SW, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: Production, characterization and sterilization. J. Control. Release. 1994;30(1):83–96.